脂肪乳(C14～24)(Fat Emulsion(C14-24)) - 在研适应症：必需脂肪酸缺乏症_专利_临床

概要

基本信息

药物类型

小分子化药

别名

Fat Emulsion(C14-24)、大豆油/卵磷脂、脂肪乳(C14-24)

+ [2]

靶点-

作用机制-

治疗领域

内分泌与代谢疾病

在研适应症

必需脂肪酸缺乏症

非在研适应症-

原研机构

Fresenius Kabi Deutschland GmbH

在研机构

Fresenius Kabi Deutschland GmbH

费森尤斯卡比华瑞制药有限公司

非在研机构-

最高研发阶段批准上市

首次获批日期

美国 (1975-10-07),

必需脂肪酸缺乏症

最高研发阶段(中国)批准上市

特殊审评-

登录后查看时间轴

关联

23

项与脂肪乳(C14～24) 相关的临床试验

CTRI/2023/11/060068 / Completed临床4期

Effect of Post-conditioning with Intralipid in Patients Undergoing Off - Pump Coronary Artery Bypass Surgery - NIL

开始日期2023-12-30

申办/合作机构-

CTRI/2023/11/059964 / Not yet recruiting临床3期IIT

CARDIOPROTECTIVE EFFECT OF INTRALIPID IN OFF PUMP CORONARY ARTERY BY PASS SURGERY ; PROSPECTIVE RANDOMIZED CONTROL STUDY IN DEPARTMENT OF ANAESTHESIA , SMS MEDICAL COLLEGE JAIPUR - nil

开始日期2023-11-23

申办/合作机构-

NCT06078345 / RecruitingN/AIIT

Brown Adipose Tissue as Nutrient Buffer Through Diet Induced Thermogenesis

To test the hypothesis that active BAT improves metabolic health by buffering postprandial metabolites plasma metabolites and energy expenditure will be compared in volunteers with and without active BAT. Both groups will receive test meals with protein, fat and carbohydrates separately, so that the individual impacts of these macronutrients on diet induced thermogenesis and the buffering function of BAT can be derived. BAT biopsies will be taken before and after the test meals for molecular analysis.

开始日期2023-10-12

申办/合作机构

Universitätsspital Basel

100 项与脂肪乳(C14～24) 相关的临床结果

登录后查看更多信息

100 项与脂肪乳(C14～24) 相关的转化医学

登录后查看更多信息

100 项与脂肪乳(C14～24) 相关的专利（医药）

登录后查看更多信息

2,489

项与脂肪乳(C14～24) 相关的文献（医药）

2025-01-01·Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy

Investigation on concentration detection of turbid solution based on hemisphere sample cell and multidimensional spectroscopy

Article

作者: Ji, Wenlong ; Zheng, Huayan ; Xu, Yun ; Zhang, Jianxin

The study developed a hemisphere sample cell and constructed a multidimensional spectroscopy acquisition system to enhance the accuracy of detecting turbid solution with scattering properties. The system simultaneously captures absorption and scattering information from the tested samples. Monte Carlo simulation was employed to model the transmission light intensity distribution data from sample cells of various shapes. It was found that the hemisphere sample cell increases the dimensionality of transmission light intensity information and enables the acquisition of more scattering-related data. Furthermore, 46 samples of intralipid-20% solution with varying concentrations were examined. Models were constructed using partial least squares (PLS) regression with one-dimensional and two-dimensional light intensity distribution data. The results indicate that the model using two-dimensional light intensity distribution data significantly outperforms the model using one-dimensional data, reducing the root mean square error by 39.96% and increasing the correlation coefficient by 0.332%. Experimental results demonstrate that the multidimensional spectroscopic modeling method employing the hemisphere sample cell can significantly enhance the accuracy and speed of detecting chemical composition concentrations in turbid solution.

2024-12-01·Neuropeptides

Enteroendocrine cell-derived peptide YY signalling is stimulated by pinolenic acid or Intralipid and involves coactivation of fatty acid receptors FFA1, FFA4 and GPR119

Article

作者: Moodaley, Runisha ; Cox, Helen M. ; Tough, Iain R ; Cox, Helen M ; Tough, Iain R.

Long chain fatty acids are sensed by enteroendocrine L cells that express free-fatty acid receptors, including FFA1, FFA4 and the acylethanolamine receptor GPR119. Here we investigated the acute effects of single or multiple agonism at these G protein-coupled receptors in intestinal mucosae where L cell-derived peptide YY (PYY) is anti-secretory and acts via epithelial Y₁ receptors. Mouse ileal or colonic mucosae were mounted in Ussing chambers, voltage-clamped and the resultant short-circuit current (I_sc) recorded continuously. The agonists used were; FFA1, TAK-875 or AM-1638; for FFA4, Merck A; or for GPR119, AR231453, PSN632408 or AR440006. Their responses were compared with those of pinolenic acid (PA, a presumed dual FFA1/FFA4 agonist) and the lipid emulsion, Intralipid. The FFA1 agonist AM-1638 (EC₅₀ = 38.2 nM) was more potent than TAK-875 (EC₅₀ = 203.1 nM) but exhibited similar efficacy. GPR119 agonism (AR231453) pretreatment enhanced subsequent FFA1 (AM-1638 or TAK-875) and FFA4 (Merck A) signalling. PA (EC₅₀ = 298.2 nM) co-activated epithelial FFA1 and FFA4 and involved endogenous PYY Y₁/Y₂-receptor mechanisms but desensitisation was observed between PA and high GPR119 agonist concentrations. Apical Intralipid co-activated FFA1, FFA4 and GPR119 with a residual component not being attributable to PYY, or this trio of fatty acid receptors.

2024-11-26·Clinical Chemistry and Laboratory Medicine (CCLM)

Quantification of C1 inhibitor activity using a chromogenic automated assay: analytical and clinical performances

Article

作者: Renaudineau, Yves ; Puissant-Lubrano, Bénédicte ; Sailler, Laurent

AbstractObjectivesThe quantification of functional C1 inhibitor activity (fC1-INH) is an important tool to diagnose bradykinin-mediated angioedema (AE), whether hereditary or acquired. For that an accurate assay is necessary, therefore we evaluated the analytical performances of a fC1-INH chromogenic assay (Berichrom®, Siemens) performed utilizing an Optilite turbidimeter (Binding Site).MethodsfC1-INH was quantified by means of the chromogenic assay Berichrom®. Internal quality controls were used to determine the precision of the assay. Stability under various storage and matrix conditions, uncertainty, linearity, interference (of hemolysis, lipemia, and icterus), agreement with the manual Technochrom® assay, and diagnostic performances were further evaluated on samples from patients and healthy donors.ResultsThe fC1-INH Berichrom® assay presented good performances regarding intra- and inter-assay precision (CV: 1.3–4.5 % and 3.0–6.0 %, respectively), expanded uncertainty (5.5 % at normal level and 12.5 % at the clinical threshold) and linearity (rho2>0.99: range 7–130 % activity). Addition of interfering substances (hemoglobin <16 g/L, intralipid® <12 g/L, and bilirubin <1 g/L) did not affect fC1-INH quantification. fC1-INH activity from healthy donors remained stable in citrate whole blood until 4 days at room temperature, and 7 days when plasma was collected. Agreement between the automated Berichrom® assay and the manual Technochrom® assay (n=47) was excellent as obtained with both quantitative (Deming regression and Bland–Altman difference plot) and qualitative (Kappa index=1) analyses. Finally, the diagnostic performance of the quantification of fC1-INH for AE evaluated on 81 patients revealed a sensitivity of 100 %, a specificity of 97.2 %, a positive predictive value of 83.3 % and a negative predictive value of 100 %.ConclusionsThe automated fC1-INH Berichrom® assay showed good performance, both at the analytical and diagnostic/clinical levels that allowed its usage in a clinical laboratory for C1-INH-dependent bradykinin-mediated AE research in combination with quantitative C1-INH and C4 determinations.

100 项与脂肪乳(C14～24) 相关的药物交易

登录后查看更多信息

研发状态

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
必需脂肪酸缺乏症	美国	Fresenius Kabi Deutschland GmbH	1975-10-07

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


ADA2024	N/A	-	-	Intralipid	選築繭廠觸鑰壓廠鏇窪(餘簾簾襯襯襯淵鹽鏇壓) = 糧選獵範獵簾壓願鬱窪積鬱繭壓醖齋範憲積膚 (鑰積選夢鹹鬱鏇淵鹽窪 ) 更多	-	2024-06-14
				Saline	選築繭廠觸鑰壓廠鏇窪(餘簾簾襯襯襯淵鹽鏇壓) = 繭繭廠衊糧範艱築蓋鏇積鬱繭壓醖齋範憲積膚 (鑰積選夢鹹鬱鏇淵鹽窪 ) 更多
NCT00672854 (TPN2, CTgov)	临床2/3期	膳食补充剂 \| 应激氧化	100	Intralipid (Total Parenteral Nutrition (TPN) Given Intralipid 20%)	鹹艱艱鑰觸壓壓構廠鹹(築積鏇餘繭窪獵遞製製) = 願蓋鹹鹹構襯簾繭觸鏇網製餘糧蓋膚積膚醖憲 (選遞製壓淵繭餘繭願積, 憲壓顧範糧積獵齋鏇積 ~ 鹽築願齋淵鹽壓淵窪餘) 更多	-	2014-08-01
				ClinOleic (Total Parenteral Nutrition (TPN) Given ClinOleic 20%)	鹹艱艱鑰觸壓壓構廠鹹(築積鏇餘繭窪獵遞製製) = 選繭積壓鬱蓋鏇鑰鏇艱網製餘糧蓋膚積膚醖憲 (選遞製壓淵繭餘繭願積, 艱醖壓壓夢鬱廠齋願鹹 ~ 衊餘鹽鑰廠鏇製構窪憲) 更多
NCT01096771 (CTgov)	临床2期	成人呼吸窘迫综合征	14	ClinOleic (Experimental ClinOleic 20%)	選膚廠壓窪鑰鏇網築繭(膚簾遞淵窪齋艱願構襯) = 廠選襯範鏇壓壓鏇製餘蓋襯餘構鹽構積餘廠鬱 (衊構遞齋鏇齋壓窪憲築, 夢廠餘餘繭襯壓襯淵製 ~ 鹹膚壓鏇顧餘獵淵糧選) 更多	-	2014-05-26
				Intralipid (Control: Intralipid 20%)	選膚廠壓窪鑰鏇網築繭(膚簾遞淵窪齋艱願構襯) = 艱範膚廠鹹構顧鹹顧淵蓋襯餘構鹽構積餘廠鬱 (衊構遞齋鏇齋壓窪憲築, 觸鹹襯齋壓鏇廠夢蓋鹹 ~ 齋鬱顧壓製願齋製醖醖) 更多